Human Epidermal Growth Factor Receptor-3 MRNA Expression As a Prognostic Marker for Invasive Duct Carcinoma Not Otherwise Specified

Overview

Journal J Clin Diagn Res

Specialty General Medicine

Date 2017 Apr 8

PMID 28384967

Citations 1

Authors

Ghada Ezat Hammoda

Sally Mohammed El-Hefnawy

Asmaa Gaber Abdou

Rania Abdallah Abdallah

Affiliations

Soon will be listed here.

Abstract

Introduction: Breast cancer is the most common cancer in women and the Erythroblastosis Oncogene B(ErbB) receptor family holds crucial role in its pathogenesis. Human Epidermal Growth Factor Receptor 3 ( gene over expression in breast tissue has been associated with aggressive clinical behaviour and bad prognosis.

Aim: To evaluate mRNA expression level as a prognostic marker for breast cancer and to correlate its level with other established prognostic parameters.

Materials And Methods: This study was carried out on specimens of 100 cases that were divided into 40 patients presented with fibroadenoma and 60 patients presented with Invasive Ductal Carcinoma (IDC) not otherwise specified and underwent modified radical mastectomy. All specimens were investigated for , ER and PR expression by Immunohistochemistry (IHC) and quantitative assay of mRNA expression using real time PCR technique.

Results: There was a significant high mRNA level in carcinoma cases compared to fibroadenoma. In malignant cases, mRNA level was significantly associated with advanced T stage, advanced N stage, number of positive lymph nodes, large tumour size and cases associated with an adjacent in situ component. Moreover, mRNA level was of highest values in Her-2/neu positive group followed by triple negative cases with the lowest level in luminal group (p<0.05).

Conclusion: gene is upregulated in IDC especially those carrying poor prognostic features. mRNA level may identify a subset of patients with a poor prognosis, and who could undergo further evaluation for the efficacy of targeted anticancer therapy.

Citing Articles

Immunoconjugates as an Efficient Platform for Drug Delivery: A Resurgence of Natural Products in Targeted Antitumor Therapy.

Mihaylova R, Momekova D, Elincheva V, Momekov G Pharmaceuticals (Basel). 2025; 17(12.

PMID: 39770542 PMC: 11677665. DOI: 10.3390/ph17121701.

Phosphorylated HER3 and FITC-labeled trastuzumab immunohistochemistry in patients with HER2-positive breast cancer treated with adjuvant trastuzumab.

Kanomata N, Kurebayashi J, Moriya T Med Mol Morphol. 2018; 52(2):106-113.

PMID: 30317526 DOI: 10.1007/s00795-018-0208-9.

References

Witton C, Reeves J, Going J, Cooke T, Bartlett J . Expression of the HER1-4 family of receptor tyrosine kinases in breast cancer. J Pathol. 2003; 200(3):290-7. DOI: 10.1002/path.1370. View

Lee Y, Cho S, Seo J, Shin B, Kim H, Kim I . Correlated expression of erbB-3 with hormone receptor expression and favorable clinical outcome in invasive ductal carcinomas of the breast. Am J Clin Pathol. 2007; 128(6):1041-9. DOI: 10.1309/GA5VRFQFY5D0MVKD. View

Neve R, Lane H, Hynes N . The role of overexpressed HER2 in transformation. Ann Oncol. 2001; 12 Suppl 1:S9-13. DOI: 10.1093/annonc/12.suppl_1.s9. View

Aubele M, Auer G, Walch A, Munro A, Atkinson M, Braselmann H . PTK (protein tyrosine kinase)-6 and HER2 and 4, but not HER1 and 3 predict long-term survival in breast carcinomas. Br J Cancer. 2007; 96(5):801-7. PMC: 2360069. DOI: 10.1038/sj.bjc.6603613. View

Hirko K, Soliman A, Hablas A, Seifeldin I, Ramadan M, Banerjee M . Trends in Breast Cancer Incidence Rates by Age and Stage at Diagnosis in Gharbiah, Egypt, over 10 Years (1999-2008). J Cancer Epidemiol. 2013; 2013:916394. PMC: 3824336. DOI: 10.1155/2013/916394. View

Wang E, Miller L, Ohnmacht G, Liu E, Marincola F . High-fidelity mRNA amplification for gene profiling. Nat Biotechnol. 2000; 18(4):457-9. DOI: 10.1038/74546. View

Ren X, Wang J, Osada T, Mook Jr R, Morse M, Barak L . Perhexiline promotes HER3 ablation through receptor internalization and inhibits tumor growth. Breast Cancer Res. 2015; 17:20. PMC: 4358700. DOI: 10.1186/s13058-015-0528-9. View

Hirata B, Oda J, Guembarovski R, Ariza C, Oliveira C, Watanabe M . Molecular markers for breast cancer: prediction on tumor behavior. Dis Markers. 2014; 2014:513158. PMC: 3925609. DOI: 10.1155/2014/513158. View

Roskoski Jr R . The ErbB/HER family of protein-tyrosine kinases and cancer. Pharmacol Res. 2013; 79:34-74. DOI: 10.1016/j.phrs.2013.11.002. View

10.

Travis A, Pinder S, Robertson J, Bell J, Wencyk P, Gullick W . C-erbB-3 in human breast carcinoma: expression and relation to prognosis and established prognostic indicators. Br J Cancer. 1996; 74(2):229-33. PMC: 2074568. DOI: 10.1038/bjc.1996.342. View

11.

Wolff A, Hammond M, Schwartz J, Hagerty K, Allred D, Cote R . American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol. 2006; 25(1):118-45. DOI: 10.1200/JCO.2006.09.2775. View

12.

Kalemi T, T Papazisis K, Lambropoulos A, Voyatzi S, Kotsis A, Kortsaris A . Expression of the HER family mRNA in breast cancer tissue and association with cell cycle inhibitors p21(waf1) and p27(kip1). Anticancer Res. 2007; 27(2):913-20. View

13.

Elston C, Ellis I . Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology. 1991; 19(5):403-10. DOI: 10.1111/j.1365-2559.1991.tb00229.x. View

14.

Bilalovic N, Sandstad B, Golouh R, Nesland J, Selak I, Torlakovic E . CD10 protein expression in tumor and stromal cells of malignant melanoma is associated with tumor progression. Mod Pathol. 2004; 17(10):1251-8. DOI: 10.1038/modpathol.3800174. View

15.

Olayioye M . Update on HER-2 as a target for cancer therapy: intracellular signaling pathways of ErbB2/HER-2 and family members. Breast Cancer Res. 2001; 3(6):385-9. PMC: 138705. DOI: 10.1186/bcr327. View

16.

Eccles S, Aboagye E, Ali S, Anderson A, Armes J, Berditchevski F . Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer. Breast Cancer Res. 2013; 15(5):R92. PMC: 3907091. DOI: 10.1186/bcr3493. View

17.

Shi F, Telesco S, Liu Y, Radhakrishnan R, Lemmon M . ErbB3/HER3 intracellular domain is competent to bind ATP and catalyze autophosphorylation. Proc Natl Acad Sci U S A. 2010; 107(17):7692-7. PMC: 2867849. DOI: 10.1073/pnas.1002753107. View

18.

Amin D, Campbell M, Moasser M . The role of HER3, the unpretentious member of the HER family, in cancer biology and cancer therapeutics. Semin Cell Dev Biol. 2010; 21(9):944-50. PMC: 2991618. DOI: 10.1016/j.semcdb.2010.08.007. View

19.

Miller T, Perez-Torres M, Narasanna A, Guix M, Stal O, Perez-Tenorio G . Loss of Phosphatase and Tensin homologue deleted on chromosome 10 engages ErbB3 and insulin-like growth factor-I receptor signaling to promote antiestrogen resistance in breast cancer. Cancer Res. 2009; 69(10):4192-201. PMC: 2724871. DOI: 10.1158/0008-5472.CAN-09-0042. View

20.

Jiang N, Saba N, Chen Z . Advances in Targeting HER3 as an Anticancer Therapy. Chemother Res Pract. 2012; 2012:817304. PMC: 3502787. DOI: 10.1155/2012/817304. View